



899 NORTH CAPITOL ST. NE – 2ND FLR. WASHINGTON, DC 20002

February 3, 2022

9:30 am

OPEN SESSION AGENDA (VIA ZOOM MEETING DUE TO THE COVID-19 PUBLIC HEALTH EMERGENCY)

Board of Pharmacy Mission Statement:

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

CALL	. TO	ORD	ER:

	FS		

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS:	- , 	
DOARD INICINIDERS:	DR. TAMARA MCCANTS, PHARM.D. R.PH CHAIRPERSON	
	MR. ALAN FRIEDMAN, R.PH, VICE CHAIRPERSON	
	DR. BENJAMIN MILES, PHARM.D. R.PH	
	DR. ASHLEE BOW, PHARM.D. R.PH	
	DR. ALLISON HILL, PHARM.D. R.PH	
	DR. ALLISON HILL, PHARM.D. R.PH	
CT.4.55		
STAFF:	DR. JUSTIN ORTIQUE, INTERIM EXECUTIVE DIRECTOR	
	Karin Barron, Health Licensing Specialist	
	Luanne Greenaway, Program specialist	
	Countee Gilliam, Board Investigator	
LEGAL STAFF:	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	
	,	
VISITORS:		
	I .	_1

Open Session Agenda

Quorum:

Introduction:		
0203-O-01	Approval of the Open Session Meeting Minutes for: December 2, 2021 January 6, 2022	
Consent Agenda	None	
<u>Chairperson</u> <u>Report</u>	Interprofessional Workgroup	Dr. Tamara McCants
Executive Director Report	 Statistical Report on Pharmacy professionals in the District of Columbia Prescription Drug Monitoring Program Updates DCRx (DC Center for Rational Prescribing) Workforce Survey 	Dr. Justin Ortique
Senior Assistant General Counsel Report		
0203-0-02	None	Ms. Carla Williams
<u>Subcommittee</u> <u>Reports</u>		
0203-O-03	Legislative and Regulatory Subcommittee Report	Mr. Alan Friedman
0203-O-04	Communications Subcommittee Report	Dr. Ashlee Bow
Presentation		
0203-O-05	COVID-19 Vaccine Planning Team Lead Heather Burris, MPH COVID-19 Vaccine Presentation This presentation is catered specifically to independent pharmacies	Dr. Heather Burris, MPH
	providing the COVID-19 Vaccine Booster.	
NABP E- Newsletter	January 26, 2022 NABP Supports Efforts to Improve Pharmacist Workplace Safety and Well-Being to Safeguard Patient Safety	Dr. Tamara McCants

NABP, Other Health Care Organizations Support Efforts to Revise NPDB's Basis for Action Codes and Descriptions	
Warning For Prescribers – Risks of Dental Problems Associated With Buprenorphine	
Study Shows Patients Are Putting a High Level of Trust in Pharmacists for Care Management	
Lohxa LLC Issues Voluntary Recall of Senna Syrup	
Adults and Type 1 Diabetes – How Pharmacists Can Help	
January 19, 2022	
New York City to Install Public Health Vending Machines With Naloxone, Other Supplies to Combat Opioid Epidemic	
NABP Explores Regulatory Trends on E-Prescribing and the Impact on the Opioid Epidemic	
January 25 FDA Drug Topics Webinar Provides Overview of Biosimilar and Interchangeable Biosimilars	
FDA Continues to Resolve iPLEDGE Data, Access Issues	
Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/.	
"Madam Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(4): "POLL CALL YOTE"	
	NPDB's Basis for Action Codes and Descriptions Warning For Prescribers – Risks of Dental Problems Associated With Buprenorphine Study Shows Patients Are Putting a High Level of Trust in Pharmacists for Care Management Lohxa LLC Issues Voluntary Recall of Senna Syrup Adults and Type 1 Diabetes – How Pharmacists Can Help January 19, 2022 New York City to Install Public Health Vending Machines With Naloxone, Other Supplies to Combat Opioid Epidemic NABP Explores Regulatory Trends on E-Prescribing and the Impact on the Opioid Epidemic January 25 FDA Drug Topics Webinar Provides Overview of Biosimilar and Interchangeable Biosimilars FDA Continues to Resolve iPLEDGE Data, Access Issues Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/. "Madam Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D. C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at _:_ AM.

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.